EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)

Carlos López López, Mariona Calvo, Juan Carlos Cámara, Beatriz García-Paredes, Carlos Gómez-Martin, Ana María López, Roberto Pazo-Cid, Javier Sastre, Ricardo Yaya, Jaime Feliu

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03568-4 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Carlos López López und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, H. U. Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Cantabria, Spain. carlos.lopez@scsalud.es. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularHumansNeoplasm StagingCombined Modality TherapyMedical Oncology

Stichwörter der Autor:innen

DiagnosticGuidelinesHepatocellular carcinomaStagingTreatment

Autor:innen und Institutionen

  • Medical Oncology Department, H. U. Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Cantabria, Spain. carlos.lopez@scsalud.es.
  • Medical Oncology Department, Institut Català d'Oncologia-L'Hospitalet del Llobregat, Barcelona, Spain.
  • Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario de Burgos, Burgos, Spain.

Zitieren

APA

López, C. L., Calvo, M., Cámara, J. C., García-Paredes, B., Gómez-Martin, C., López, A. M., Pazo-Cid, R., Sastre, J., Yaya, R., & Feliu, J. (2024). SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023). Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03568-4

Vancouver

López CL, Calvo M, Cámara JC, García-Paredes B, Gómez-Martin C, López AM, et al. SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023). Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03568-4

BibTeX
@article{Lpez2024,
  author = {López, Carlos López and Calvo, Mariona and Cámara, Juan Carlos and García-Paredes, Beatriz and Gómez-Martin, Carlos and López, Ana María and Pazo-Cid, Roberto and Sastre, Javier and Yaya, Ricardo and Feliu, Jaime},
  title = {SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03568-4}
}
Kostenlos starten →